pegcetacoplan

Showing 1 posts of 1 posts found.

shutterstock

Apellis therapy outflanks Alexion’s Soliris in head-to-head paroxysmal nocturnal haemoglobinuria

January 8, 2020
Research and Development Alexion, Appelis, pegcetacoplan, pharma, soliris

Apellis Pharmaceuticals has revealed new Phase 3 demonstrating that its targeted C3 inhibitor pegcetacoplan met its primary endpoint and outclassed …

The Gateway to Local Adoption Series

Latest content